- Home
- REGN vs CNI Comparison
REGN vs CNI Comparison
Compare REGN & CNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- CNI
- Stock Information
- Founded
- REGN 1988
- CNI 1919
- Country
- REGN United States
- CNI Canada
- Employees
- REGN N/A
- CNI N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- CNI
- Sector
- REGN Health Care
- CNI
- Exchange
- REGN Nasdaq
- CNI Nasdaq
- Market Cap
- REGN 63.4B
- CNI 61.7B
- IPO Year
- REGN 1991
- CNI N/A
- Fundamental
- Price
- REGN $527.78
- CNI $100.43
- Analyst Decision
- REGN Buy
- CNI Hold
- Analyst Count
- REGN 23
- CNI 15
- Target Price
- REGN $907.39
- CNI $118.95
- AVG Volume (30 Days)
- REGN 1.3M
- CNI 1.4M
- Earning Date
- REGN 04-29-2025
- CNI 05-01-2025
- Dividend Yield
- REGN 0.33%
- CNI 2.45%
- EPS Growth
- REGN 16.49
- CNI N/A
- EPS
- REGN 39.43
- CNI 4.97
- Revenue
- REGN $14,085,700,000.00
- CNI $11,966,466,061.00
- Revenue This Year
- REGN $2.38
- CNI $6.12
- Revenue Next Year
- REGN $7.65
- CNI $5.48
- P/E Ratio
- REGN $13.39
- CNI $20.10
- Revenue Growth
- REGN 7.52
- CNI 2.60
- 52 Week Low
- REGN $525.99
- CNI $91.65
- 52 Week High
- REGN $1,211.20
- CNI $129.18
- Technical
- Relative Strength Index (RSI)
- REGN 35.08
- CNI 55.32
- Support Level
- REGN $520.50
- CNI $98.03
- Resistance Level
- REGN $615.61
- CNI $101.44
- Average True Range (ATR)
- REGN 22.65
- CNI 2.21
- MACD
- REGN -2.54
- CNI 0.42
- Stochastic Oscillator
- REGN 7.65
- CNI 82.86
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About CNI Canadian National Railway Company
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2024, CN generated CAD 17 billion in revenue by hauling intermodal containers (22% of consolidated revenue), petroleum and chemicals (20%), grain and fertilizers (20%), forest products (11%), metals and minerals (12%), automotive shipments (5%), and coal (5%). Other items constitute the remaining revenue.